Buprenorphine: Difference between revisions
ClaireLewis (talk | contribs) (Created page with "==Administration== *Type: Opioid- maintenance therapy in opioid use disorder, rapid detox *Dosage Forms: *Routes of Administration: Buccal, sublingual, intradermal, transd...") |
(edited dosage forms, strengths, routes of administration, trade names) |
||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: [[Opioid]]- maintenance therapy in opioid use disorder, rapid detox | *Type: [[Opioid]]- maintenance therapy in opioid use disorder, rapid detox | ||
*Dosage Forms: | *Dosage Forms: injectable solution, sublingual tablet | ||
*Routes of Administration: Buccal, sublingual, intradermal, transdermal, IV | *Dosage Strengths: injectable solution: 0.3 mg/mL; sublingual tablet: 2, 8mg | ||
*Common Trade Names: Suboxone (buprenorphine + [[naloxone]]) | *Routes of Administration: Buccal, sublingual, intradermal, transdermal, IV, IM | ||
*Common Trade Names: Suboxone (buprenorphine + [[naloxone]]), Buprex | |||
==Adult Dosing== | ==Adult Dosing== | ||
Revision as of 23:24, 11 October 2017
Administration
- Type: Opioid- maintenance therapy in opioid use disorder, rapid detox
- Dosage Forms: injectable solution, sublingual tablet
- Dosage Strengths: injectable solution: 0.3 mg/mL; sublingual tablet: 2, 8mg
- Routes of Administration: Buccal, sublingual, intradermal, transdermal, IV, IM
- Common Trade Names: Suboxone (buprenorphine + naloxone), Buprex
Adult Dosing
Highly variable dependent on individual
Pediatric Dosing
Variable
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk has been demonstrated
- Hepatic dosing: reduce dose or do not use in moderate - severe impairment
- Renal dosing:
Contraindications
- Allergy to class/drug
- SBO, paralytic ileus
- Acute/severe asthma (if unmonitored), respiratory depression
Adverse Reactions
Serious
- Hypotension, prolonged QT, MI
- Respiratory depression
- SBO
- Hepatotoxicity
- Stroke
- Sedation, coma
- Drug dependence or withdrawal
Common
- Pruritus
- Constipation, nausea, diarrhea, xerostomia
- Dizziness, headache, somnolence
- URI symptoms
Pharmacology
- Half-life: 24-48 hours
- Metabolism: Extensive hepatic, CYP3A4 substrate
- Excretion: Mostly fecal, some renal
Mechanism of Action
- Mixed opiate agonist-antagonist, partial mu-opioid agonist, kappa-opioid antagonist